ALX Oncology Holdings Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALXO Nasdaq 2830 www.alxoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ALX Oncology Holdings Inc.

ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs - Jun 3rd, 2026 9:02 pm
ALX Oncology (ALXO) Q1 2026 Earnings Transcript - Jun 1st, 2026 11:23 am
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York - Jun 1st, 2026 6:00 am
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - May 12th, 2026 7:40 am
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary - May 9th, 2026 6:30 am
ALX Oncology Q1 Earnings Call Highlights - May 8th, 2026 8:57 am
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 8th, 2026 6:00 am
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - May 7th, 2026 6:00 am
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock - May 2nd, 2026 6:32 am
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 - Apr 30th, 2026 6:00 am
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - Apr 17th, 2026 2:05 pm
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - Apr 16th, 2026 7:55 am
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Apr 13th, 2026 6:30 am
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA - Mar 18th, 2026 9:10 am
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - Mar 17th, 2026 8:40 am
IBRX Stock Jumps on Progress in NK Cell Therapy Production - Mar 16th, 2026 11:35 am
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study - Mar 16th, 2026 10:59 am
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - Mar 13th, 2026 9:24 am
ALX Oncology initiated with a Buy at UBS - Mar 7th, 2026 6:25 am
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Mar 6th, 2026 8:26 am